About this episode
Dr Amar Kishan (Radiation Oncologist, UCLA, USA), made lots of headlines recently when he presented data from the phase II randomised LUNAR trial of SABR +/- LuPSMA in patients with oligometastatic prostate cancer. So we were very happy when he turned up in Melbourne recently and popped into the GU Cast studio for a chat. We discuss metastasis-directed therapy and bring up our favourite Pokemet analogies, and ask should we not just be offering these patients and ADT/ARPI doublet?!
Regular hosts Declan Murphy and Renu Eapen, also joined by Prof Wee Ong, Radiation Oncologist at Alfred Health in Melbourne.
This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson.
Even better on our YouTube channel
Get every episode summarized
Each time GU Cast | Urology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from GU Cast | Urology Podcast
Is Copper the new Gold??! Co-PSMA trial in European Urology
GU Cast | Urology Podcast
EAU Prostate Cancer Guideline Update
GU Cast | Urology Podcast
Journal club #7 | proPSMA and Penile Fractures(!)
GU Cast | Urology Podcast
ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
GU Cast | Urology Podcast